With venture investments pouring into biopharma, steady M&A deals and an increasingly widening IPO market, J.P. Morgan sees the industry returning to growth—finally.

Venture dollars rose in the second quarter compared to the one prior, according to a new second-quarter licensing and venture report from the bank. Biopharmas raised $7.6 billion in private financings across 107 investments, with the dollar value for both the second and first quarters beating the previous ones. The first quarter also saw 107 total rounds. READ MORE